End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
35 NZD | +2.34% | -0.71% | -1.41% |
Summary
- Overall, and from a short-term perspective, the company presents an interesting fundamental situation.
Strengths
- The company is one of the most undervalued, with an "enterprise value to sales" ratio at 0.56 for the 2024 fiscal year.
- Sales forecast by analysts have been recently revised upwards.
- There is high visibility into the group's activities for the coming years. Outlooks on future revenues from analysts covering the equity remain similar. Such hardly dispersed estimates support highly predictable sales for the current and upcoming fiscal years.
Weaknesses
- According to Standard & Poor's' forecast, revenue growth prospects are expected to be very low for the next fiscal years.
- The potential for earnings per share (EPS) growth in the coming years appears limited according to current analyst estimates.
- The company's profitability before interest, taxes, depreciation and amortization characterizes fragile margins.
- The company sustains low margins.
- With a 2024 P/E ratio at 21.84 times the estimated earnings, the company operates at rather significant levels of earnings multiples.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Pharmaceuticals
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
-1.41% | 4.08B | B- | ||
+19.14% | 71.7B | C+ | ||
-3.34% | 23.73B | C+ | ||
+10.27% | 9.01B | C | ||
+12.67% | 8.72B | B | ||
-17.41% | 8.29B | B- | ||
+9.65% | 5B | B- | ||
+21.40% | 4.48B | B+ | ||
-1.99% | 3.92B | B | ||
+27.43% | 3.8B | C+ |
Financials
Valuation
Momentum
Consensus
Business Predictability
Environment
Governance
Controversy
Technical analysis
- Stock Market
- Equities
- EBO Stock
- Ratings EBOS Group Limited